Annual CFF
$221.32 M
-$294.85 M-57.12%
31 December 2023
Summary:
Cytokinetics Incorporated annual cash flow from financing activities is currently $221.32 million, with the most recent change of -$294.85 million (-57.12%) on 31 December 2023. During the last 3 years, it has fallen by -$12.81 million (-5.47%). CYTK annual CFF is now -57.12% below its all-time high of $516.17 million, reached on 31 December 2022.CYTK Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.42 M
-$817.59 M-99.58%
30 September 2024
Summary:
Cytokinetics Incorporated quarterly cash flow from financing activities is currently $3.42 million, with the most recent change of -$817.59 million (-99.58%) on 30 September 2024. Over the past year, it has dropped by -$50.79 million (-93.68%). CYTK quarterly CFF is now -99.58% below its all-time high of $821.01 million, reached on 30 June 2024.CYTK Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$1.10 B
-$50.79 M-4.43%
30 September 2024
Summary:
Cytokinetics Incorporated TTM cash flow from financing activities is currently $1.10 billion, with the most recent change of -$50.79 million (-4.43%) on 30 September 2024. Over the past year, it has increased by +$1.01 billion (+1231.31%). CYTK TTM CFF is now -4.43% below its all-time high of $1.15 billion, reached on 30 June 2024.CYTK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CYTK Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -57.1% | -93.7% | +1231.3% |
| 3 y3 years | -5.5% | -98.9% | +260.7% |
| 5 y5 years | +1585.3% | -71.1% | +2704.1% |
CYTK Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -57.1% | at low | -99.6% | +147.7% | -4.4% | +1231.3% |
| 5 y | 5 years | -57.1% | +1585.3% | -99.6% | +147.7% | -4.4% | +2704.1% |
| alltime | all time | -57.1% | +6513.1% | -99.6% | +147.7% | -4.4% | >+9999.0% |
Cytokinetics Incorporated Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.42 M(-99.6%) | $1.10 B(-4.4%) |
| June 2024 | - | $821.01 M(+691.0%) | $1.15 B(+245.4%) |
| Mar 2024 | - | $103.79 M(-38.5%) | $332.29 M(+50.1%) |
| Dec 2023 | $221.32 M(-57.1%) | $168.80 M(+211.3%) | $221.32 M(+168.6%) |
| Sept 2023 | - | $54.22 M(+890.3%) | $82.40 M(-80.2%) |
| June 2023 | - | $5.47 M(-176.3%) | $417.20 M(+0.5%) |
| Mar 2023 | - | -$7.18 M(-124.0%) | $415.14 M(-19.6%) |
| Dec 2022 | $516.17 M(+61.3%) | $29.89 M(-92.3%) | $516.17 M(+2.1%) |
| Sept 2022 | - | $389.02 M(>+9900.0%) | $505.79 M(+21.1%) |
| June 2022 | - | $3.42 M(-96.4%) | $417.66 M(+0.1%) |
| Mar 2022 | - | $93.85 M(+381.1%) | $417.42 M(+30.5%) |
| Dec 2021 | $319.98 M(+36.7%) | $19.51 M(-93.5%) | $319.98 M(+5.2%) |
| Sept 2021 | - | $300.89 M(+9377.0%) | $304.12 M(+32.5%) |
| June 2021 | - | $3.17 M(-188.3%) | $229.55 M(-0.4%) |
| Mar 2021 | - | -$3.60 M(-198.8%) | $230.54 M(-1.5%) |
| Dec 2020 | $234.12 M(+46.5%) | $3.64 M(-98.4%) | $234.12 M(-33.4%) |
| Sept 2020 | - | $226.33 M(+5340.7%) | $351.60 M(+156.4%) |
| June 2020 | - | $4.16 M(<-9900.0%) | $137.13 M(-11.7%) |
| Mar 2020 | - | -$11.00 K(-100.0%) | $155.36 M(-2.8%) |
| Dec 2019 | $159.79 M(+1116.8%) | $121.12 M(+921.3%) | $159.79 M(+308.4%) |
| Sept 2019 | - | $11.86 M(-47.0%) | $39.12 M(+4.4%) |
| June 2019 | - | $22.40 M(+407.2%) | $37.49 M(+107.4%) |
| Mar 2019 | - | $4.42 M(+879.2%) | $18.07 M(+37.6%) |
| Dec 2018 | $13.13 M(-94.2%) | $451.00 K(-95.6%) | $13.13 M(-11.7%) |
| Sept 2018 | - | $10.23 M(+243.4%) | $14.88 M(+144.6%) |
| June 2018 | - | $2.98 M(-668.3%) | $6.08 M(-94.5%) |
| Mar 2018 | - | -$524.00 K(-123.9%) | $109.66 M(-51.5%) |
| Dec 2017 | $225.92 M(+1237.4%) | $2.19 M(+53.0%) | $225.92 M(+0.7%) |
| Sept 2017 | - | $1.43 M(-98.7%) | $224.44 M(+0.3%) |
| June 2017 | - | $106.56 M(-7.9%) | $223.73 M(+90.0%) |
| Mar 2017 | - | $115.73 M(>+9900.0%) | $117.77 M(+597.2%) |
| Dec 2016 | $16.89 M(-29.4%) | $715.00 K(-1.7%) | $16.89 M(-57.6%) |
| Sept 2016 | - | $727.00 K(+23.4%) | $39.82 M(+1.4%) |
| June 2016 | - | $589.00 K(-96.0%) | $39.26 M(+1.4%) |
| Mar 2016 | - | $14.86 M(-37.1%) | $38.71 M(+61.9%) |
| Dec 2015 | $23.91 M(-51.1%) | $23.64 M(>+9900.0%) | $23.91 M(+154.3%) |
| Sept 2015 | - | $164.00 K(+300.0%) | $9.40 M(+1.8%) |
| June 2015 | - | $41.00 K(-36.9%) | $9.24 M(+0.1%) |
| Mar 2015 | - | $65.00 K(-99.3%) | $9.23 M(-81.1%) |
| Dec 2014 | $48.95 M | $9.13 M(>+9900.0%) | $48.95 M(+3.4%) |
| Sept 2014 | - | $0.00(-100.0%) | $47.33 M(+1.1%) |
| June 2014 | - | $35.00 K(-99.9%) | $46.81 M(-13.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $39.78 M(+429.3%) | $54.26 M(+274.5%) |
| Dec 2013 | $14.49 M(-75.2%) | $7.52 M(-1556.6%) | $14.49 M(+107.1%) |
| Sept 2013 | - | -$516.00 K(-106.9%) | $7.00 M(-1.5%) |
| June 2013 | - | $7.48 M(>+9900.0%) | $7.10 M(-87.2%) |
| Mar 2013 | - | $5000.00(-80.0%) | $55.66 M(-4.6%) |
| Dec 2012 | $58.33 M(+169.9%) | $25.00 K(-106.1%) | $58.33 M(-3.9%) |
| Sept 2012 | - | -$412.00 K(-100.7%) | $60.70 M(-0.4%) |
| June 2012 | - | $56.05 M(+2001.5%) | $60.93 M(+148.4%) |
| Mar 2012 | - | $2.67 M(+11.4%) | $24.53 M(+13.5%) |
| Dec 2011 | $21.61 M(+748.9%) | $2.39 M(-1437.4%) | $21.61 M(-10.1%) |
| Sept 2011 | - | -$179.00 K(-100.9%) | $24.03 M(+0.8%) |
| June 2011 | - | $19.65 M(-7867.2%) | $23.84 M(-6631.5%) |
| Mar 2011 | - | -$253.00 K(-105.3%) | -$365.00 K(-114.3%) |
| Dec 2010 | $2.55 M(-91.2%) | $4.81 M(-1394.1%) | $2.55 M(-199.9%) |
| Sept 2010 | - | -$372.00 K(-91.8%) | -$2.55 M(-40.4%) |
| June 2010 | - | -$4.55 M(-271.3%) | -$4.28 M(-133.5%) |
| Mar 2010 | - | $2.66 M(-1045.9%) | $12.76 M(-55.7%) |
| Dec 2009 | $28.81 M(-934.7%) | -$281.00 K(-86.6%) | $28.81 M(+1.5%) |
| Sept 2009 | - | -$2.10 M(-116.8%) | $28.39 M(-3.7%) |
| June 2009 | - | $12.48 M(-33.3%) | $29.49 M(+81.3%) |
| Mar 2009 | - | $18.71 M(-2795.5%) | $16.27 M(-571.5%) |
| Dec 2008 | -$3.45 M(-109.9%) | -$694.00 K(-30.8%) | -$3.45 M(+128.2%) |
| Sept 2008 | - | -$1.00 M(+35.5%) | -$1.51 M(-123.7%) |
| June 2008 | - | -$740.00 K(-27.0%) | $6.39 M(-4.7%) |
| Mar 2008 | - | -$1.01 M(-181.4%) | $6.71 M(-80.7%) |
| Dec 2007 | $34.72 M(-60.0%) | $1.25 M(-82.0%) | $34.72 M(-50.4%) |
| Sept 2007 | - | $6.90 M(-1719.7%) | $69.98 M(-0.6%) |
| June 2007 | - | -$426.00 K(-101.6%) | $70.39 M(-9.1%) |
| Mar 2007 | - | $27.00 M(-26.0%) | $77.40 M(-10.7%) |
| Dec 2006 | $86.72 M(+1492.4%) | $36.51 M(+399.4%) | $86.72 M(+54.6%) |
| Sept 2006 | - | $7.31 M(+11.0%) | $56.10 M(+14.4%) |
| June 2006 | - | $6.58 M(-81.9%) | $49.05 M(+16.0%) |
| Mar 2006 | - | $36.32 M(+517.7%) | $42.27 M(+676.2%) |
| Dec 2005 | $5.45 M(-94.7%) | $5.88 M(+2144.3%) | $5.45 M(+579.9%) |
| Sept 2005 | - | $262.00 K(-237.2%) | $801.00 K(+2570.0%) |
| June 2005 | - | -$191.00 K(-62.2%) | $30.00 K(-100.0%) |
| Mar 2005 | - | -$505.00 K(-140.9%) | $102.09 M(-0.2%) |
| Dec 2004 | $102.32 M(+154.3%) | $1.24 M(-342.6%) | $102.32 M(+1.2%) |
| Sept 2004 | - | -$509.00 K(-100.5%) | $101.09 M(-0.5%) |
| June 2004 | - | $101.87 M(<-9900.0%) | $101.59 M(<-9900.0%) |
| Mar 2004 | - | -$272.00 K | -$272.00 K |
| Dec 2003 | $40.24 M(+726.4%) | - | - |
| Dec 2002 | $4.87 M | - | - |
FAQ
- What is Cytokinetics Incorporated annual cash flow from financing activities?
- What is the all time high annual CFF for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated annual CFF year-on-year change?
- What is Cytokinetics Incorporated quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated quarterly CFF year-on-year change?
- What is Cytokinetics Incorporated TTM cash flow from financing activities?
- What is the all time high TTM CFF for Cytokinetics Incorporated?
- What is Cytokinetics Incorporated TTM CFF year-on-year change?
What is Cytokinetics Incorporated annual cash flow from financing activities?
The current annual CFF of CYTK is $221.32 M
What is the all time high annual CFF for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high annual cash flow from financing activities is $516.17 M
What is Cytokinetics Incorporated annual CFF year-on-year change?
Over the past year, CYTK annual cash flow from financing activities has changed by -$294.85 M (-57.12%)
What is Cytokinetics Incorporated quarterly cash flow from financing activities?
The current quarterly CFF of CYTK is $3.42 M
What is the all time high quarterly CFF for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high quarterly cash flow from financing activities is $821.01 M
What is Cytokinetics Incorporated quarterly CFF year-on-year change?
Over the past year, CYTK quarterly cash flow from financing activities has changed by -$50.79 M (-93.68%)
What is Cytokinetics Incorporated TTM cash flow from financing activities?
The current TTM CFF of CYTK is $1.10 B
What is the all time high TTM CFF for Cytokinetics Incorporated?
Cytokinetics Incorporated all-time high TTM cash flow from financing activities is $1.15 B
What is Cytokinetics Incorporated TTM CFF year-on-year change?
Over the past year, CYTK TTM cash flow from financing activities has changed by +$1.01 B (+1231.31%)